BIOMAT Database Logo BIOMAT Database Logo

[Clinical efficacy of sulbactam/ampicillin in comparison with cefotiam in the treatment of elderly patients with pneumonia]. 1998

T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Department of Internal Medicine, National Ohmuta Hospital.

Clinical efficacy and safety of pareteral sulbactam/ampicillin (SBT/ABPC) was compared with cefotiam (CTM) in a randomized clinical trial of pneumonia in the elderly at 13 National Hospitals of Kyushu island. 37 patients received SBT/ABPC 3 g i.v., b.i.d., and 31 patients received CTM 1 g i.v., b.i.d. for 7 to 14 days. 1. 68 patients (37 for SBT/ABPC and 31 for CTM) were evaluated for safety. No statistical differences were noted in the patients' backgrounds of either group. 2. The clinical efficacy of SBT/ABPC was 96.3% (26/27 cases) while CTM was 75.2% (17/23 cases). This was found to be statistically significant (Fisher's exact test: p < 0.05). 3. 100% of evaluated cases (10 for SBT/ABPC and 4 for CTM) showed bacterial elimination. 4. No side effects were observed in the study. 5. Abnormal laboratory findings were noted in 10.8% (4/37 cases) for SBT/ABPC and 3.2% (1/31 cases) for CTM. The major adverse events were mild elevation of GOT, GPT and A1-P for SBT/ABPC, and mild platelets overproduction for CTM. No statistical differences were noted in both groups. These results are consistent with SBT/ABPC as a highly effective antibiotic in the treatment of elderly patients with pneumonia.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
February 2014, Infection,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
June 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery.
January 1997, Infection,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.
January 2006, Internal medicine (Tokyo, Japan),
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Dosing Optimization of Ampicillin-Sulbactam Based on Cystatin C in Elderly Patients with Pneumonia.
January 2021, Biological & pharmaceutical bulletin,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Effects of dosing frequency on the clinical efficacy of ampicillin/sulbactam in Japanese elderly patients with pneumonia: A single-center retrospective observational study.
April 2021, Pharmacology research & perspectives,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Clinical efficacy of sulbactam/ampicillin in the treatment of moderately severe bacterial infections.
April 1989, Singapore medical journal,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
[Clinical efficacy of sulbactam/ampicillin in the field of pediatrics].
March 1989, The Japanese journal of antibiotics,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Treatment of acute salpingitis with sulbactam/ampicillin. Comparison with cefoxitin.
January 1986, Drugs,
T Ishibashi, and Y Harada, and M Takamoto, and M Ebihara, and M Sugiyama, and K Shimazu, and T Iwanaga, and R Kishikawa, and T Makie, and H Tsurutani, and K Kisanuki, and T Mitsuno, and N Hirota, and T Furuno, and T Hiraoka, and Y Tsumori, and Y Matsuura, and K Namba, and T Oe, and M Inuyama, and S Chifu, and H Fukunaga, and Y Ueno, and K Matsukizono, and K Genka
Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
June 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!